News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Philadelphia region designated a federal tech hub for life sciences
The Philadelphia region has been designated as a federal innovation and technology hub, allowing it to compete for a grant of up to $75 million to advance its life sciences industry.
Emily Whitehead, the first child to be cured of cancer with Penn-invented CAR-T therapy, is now a freshman at Penn
From American Sign Language to English to nature photography, Emily has a wide range of interests she intends to explore in her studies.
Penn Hosts IvyTech 2023 – Event Recap
Last week, PCI hosted IvyTech, an annual conference that brings together technology transfer professionals to discuss the future of research, commercialization, and intellectual property.
Penn spinout Interius Biotherapeutics raises another $21.5M
Co-founded by Saar Gill, MD, PhD, Interius is developing a new platform for cell-specific gene delivery in patients.
Penn Faculty Discover An Innovative Potential Treatment for Tooth Decay
In search of a more effective treatment, the research team employed a combination of ferumoxytol (Fer) and stannous fluoride (SnF2) to fight tooth decay.
FloBio Receives the FDA’s Breakthrough Device Designation for its Bleeding Risk Diagnostic Test
FloBio's test determines blood clotting status and identifies whether a patient is on popular blood thinners called Direct Oral Anticoagulants (DOACs).
PCI Recognized In Clinical Leader Article about How Academic Medical Centers Can Capture Greater Value In The Cell & Gene Therapy Industry
The Penn Center of Innovation was recognized in an article in Clinical Leader about how academic medical centers can leverage their unique advantages to develop and deliver cell and gene therapies.
National Academy of Medicine Elects Five Penn Experts
Five Penn experts have been elected to the National Academy of Medicine (NAM), one of the nation’s highest honors in the fields of health and medicine.
Opus Genetics Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
Penn spinout Opus Genetics announced that the first patient has been dosed in its Phase 1/2, first-in-human clinical trial of OPGx-LCA5.
Penn biomedical scientists move into new uCity complex with 115,000 square feet of lab space
A group of Penn scientists and engineers is moving into 115,000 square feet of new lab space in the 13-story One uCity Square building in West Philadelphia.